Product Description
Fleroxacin 98%min supplier Pharmaceutical API A broad-spectrum antibiotic made in china 79660-72-3
AI Product Description
*The following content is generated by AI and is for reference only.
Fleroxacin, a synthetic fluoroquinolone antibiotic with a minimum purity of 98%, is widely recognized as a potent broad-spectrum antimicrobial agent manufactured in China for global pharmaceutical markets. With the chemical formula C17H19FN4O3 and CAS Registry Number 85825-04-9, this compound functions by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes required for DNA replication, transcription, and repair. This mechanism effectively halts bacterial growth, making it particularly effective against both Gram-positive and Gram-negative organisms, including resistant strains of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.
As a third-generation fluoroquinolone, Fleroxacin exhibits superior pharmacokinetic properties compared to earlier generations, featuring high oral bioavailability, extensive tissue penetration, and a prolonged half-life that allows for once-daily dosing regimens. Its primary clinical applications involve the treatment of uncomplicated and complicated urinary tract infections, acute bacterial prostatitis, gonococcal urethritis, and various respiratory tract infections. Due to its robust efficacy profile, it is frequently utilized in veterinary medicine as well, treating similar infections in livestock and poultry to ensure food safety and animal health.
The production of high-purity Fleroxacin API in China has positioned the country as a critical hub for supplying cost-effective, quality-assured antibiotics to international pharmaceutical manufacturers. Adhering to strict Good Manufacturing Practice (GMP) standards, Chinese suppliers ensure that the final product meets rigorous international specifications regarding potency, impurity profiles, and stability. The availability of bulk quantities at competitive prices makes it an attractive option for generic drug developers aiming to expand their therapeutic portfolios. While newer fluoroquinolones have emerged, Fleroxacin remains a valuable component in the global arsenal against multidrug-resistant pathogens, provided it is used responsibly to mitigate the risk of developing further resistance. Its role in combating serious bacterial infections underscores its continued relevance in modern medical therapy and public health strategies worldwide.